Patent Application
20200299629
The present invention relates to a device for the examination of neurons and to a method for examining neurons, and more specifically for examining neurons growing in a three-dimensional network.
Dysfunctions of the central nervous system represent a major burden for society and healthcare worldwide, affecting hundreds million people every year, with many patients obtaining little or no relief from current treatments.
The identification of new drugs to safely and effectively target specific neuronal circuits represents one of the main challenges that the pharmaceutical industry needs to face for the development of new therapeutic strategies to treat human brain disorders, in particular neurodegenerative diseases. To avoid late, high attrition rates and making drug development more cost effective, potential neurotoxicity and seizure liability has to be recognized as early as possible during the discovery process.
Assessment of the potential impact of new compounds on the nervous system represents a major effort also for the agro-chemical and the consumer products industry, as these studies are required by regulatory authorities before new chemical entities can be introduced into the market.
Most of these studies rely on the use of ex vivo and in vivo animal models, which are not always predictive of adverse events in humans. They are costly and time consuming and not amenable to high throughput testing of chemicals and compounds. In addition, they are ethically questionable due to the high number of animals needed and the impact on their wellness during substance exposure.
According to a recent policy in the European Union (Regulation, Evaluation Authorization and Restriction of Chemicals, REACH), it has been estimated that over the next twelve to fifteen years, approximately 30,000 chemicals may need to be tested for safety, and under current guidelines such testing would require the use of approximately 7.2 million laboratory animals. It has also been estimated that out of 5,000 to 10,000 new drug entities that a pharmaceutical company may start with, only one is finally approved by the Food and Drug Administration at a cost of over one billion dollars. A large portion of this cost is due to animal testing.
Therefore, EU and international policies increasingly call for the reduction or replacement of in vivo animal studies in the process of drug development and toxicity testing. Thus, alternative in vitro approaches to hazard identification are needed that have higher throughput capabilities and are more predictive of in vivo effects.
Due to their intrinsic capacity to non-invasively measure the extracellular potential of hundreds or thousands of cells in parallel, in the last few years microelectrode array (MEA) recordings have become increasingly common for a variety of applications focusing on the study of neuronal networks and, more in general, excitable cells such as neurons and cardiomyocytes. This applies to both basic research and industries looking for a high-throughput, high-content assay for preclinical discovery, safety pharmacology and toxicology.
Several international groups have demonstrated that MEA recordings are very sensitive in detecting electrophysiological changes in neuronal networks. Thus MEA recordings provide a robust assay for efficacy, seizure liability and neurotoxicity testing in a variety of in vitro models. A large international consortium (CiPA Initiative), composed by public and industrial stakeholders, is evaluating MEA technology also for its possible application in the field of cardiac safety pharmacology. There, MEA technology in combination with the use of human iPSC-derived cardiomyocytes would offer an alternative to expensive and time-consuming in vivo animal models currently required by regulatory authorities.
Cells grown adherent on two-dimensional (2D) substrates do not fully represent true in vivo cell environments and lack extracellular components, cell-cell and cell-matrix interactions necessary for differentiation, proliferation and cell-based functions. More recently, three-dimensional (3D) cell culture techniques have been explored as a new opportunity in the biomedical research community. 3D cell culture techniques have demonstrated the potential to develop complex tissue structures in vitro. There is increasing evidence that 3D culture systems can capture important components of the complex physiology of a tissue or an organ better than classical monolayer approaches.
This brings the hope of lowering lead molecule attrition rates while enhancing overall predictability of in vitro assays. However, these models restrict huge data reproducibility, challenge assay readout systems and often require complex microfabrication processes. New developments in this direction, especially in throughput capabilities and disease modelling, have a great value for the identification and validation of novel targets involved in neuronal functions and dysfunctions.
In an effort to accelerate and increase the success rate of the drug-discovery process, the potential of combining and interfacing microtechnologies with brain cell populations, for example derived from human induced pluripotent stem cells (iPSCs), has recently become the focus of many pre-clinical research programs worldwide, for example at NIH (National Institutes of Health) and DARPA (Defense Advanced Research Projects Agency) in the U.S. By taking advantage of the human origin of iPSCs such new methods aim to improve predictability of a range of physiological, pharmacological and toxicological assays. To do so, several labs are attempting to create organ- and body-on-chip, looking at the possibility to generate 3D structures which, by mimicking the multicellular architecture of living organs, may better recapitulate human health and diseases.
However, as yet, there is no integrated, human relevant, in vitro 3D system or technology for assessing efficacy, neurotoxicity or seizure liability of new compounds based on the inherent physiological characteristics of the brain (i.e. electrical activity, tissue architecture, synaptic structures) that is fit for purpose for use in basic or applied research.
Brewer et al. (2013), Toward a self-wired active reconstruction of the hippocampal trisynaptic loop: DG-CA3, Front. Neural. Circuits., Vol. 7, Art. 165, p. 1-8, and Gladkov et al. (2017), Design of Cultured Neuron Networks in vitro with Predefined Connectivity Using Asymmetric Microfluidic Channels”. Sci Rep. 7(1):15625, disclose two-compartment neuron cultivation system, where both compartments are connected via microtunnels of different designs allowing the passing-through of adherent neurites. Such system is arranged on a multi-electrode array (MEA) comprising recording electrodes. Electrical activity of neurites was recorded by microelectrodes located within microtunnels, as is expected for cultured neurons adherent on MEA surfaces.
Tsantoulas et al. (2013), Probing functional properties of nociceptive axons using a microfluidic culture system, PLoS One, Vol. 8, Issue 11, p. 1-17, disclose a two-compartment neuron cultivation system, where both compartments are connected via microgrooves allowing the passing-through of neurites. Again, neurons were cultured adherent on the device surface. In the system basically a chemical stimulation is realized. In one variant an electrical stimulation occurs. A so-called field potential stimulation takes place via macroscopic “electrodes” in the form of simple wires placed into the cultivation compartment. Activity of neurons is mainly read out by calcium imaging, which only indirectly estimates electrical activity and does not match the temporal resolution of electrical recording. In addition, activity of neurons is recorded via the patch-clamp method, which is invasive and has negative effects on the architecture and integrity of the neurons.
The WO 2004/034016 discloses a two-compartment microfluidic device where the two compartments are coupled by a barrier comprising micron sized grooves. It is mentioned that positive or negative stimuli may be selectively applied to distal portions of the neurites, growing adherently to one of the surfaces of the device, at the point of the barrier with the grooves or channels, respectively.
The US 2004/230270 discloses an interface for selectively making electrical contact to a plurality of neural cells in a biological neural network, wherein said biological network comprises a brain cortex or retinal neural network. It is mentioned that spatially resolved electrical contact to neural cells can be made by allowing migration of cell soma into microchannels.
Further devices for the examination of neurons are known from Navarro et al. (2005), A critical review of interfaces with the peripheral nervous system for the control of neuroprostheses and hybrid bionic systems. J. Peripher. Nerv. Syst. 10(3):229-58; Zhuang et al. (2017), 3D neural tissue models: From spheroids to bioprinting. Biomaterials 154:113-133; Wang et al. (2012), Biophysics of microchannel-enabled neuron-electrode interfaces. J. Neural. Eng. 9(2):026010; Fitzgerald et al. (2008), Microchannels as axonal amplifiers. IEEE Trans. Biomed. Eng. 55(3):1136-46; U.S. Pat. No. 3,955,560; EP 2 249 915; US 2017/311,827
So far the known devices and methods did not prove particular successful in supporting development of new therapeutic intervention for neuronal disorders in human patients. In particular, they often fail to mimic the physiological complexity that characterizes neural networks. As yet, there is no integrated, human relevant, in vitro 3D system for assessing efficacy, neurotoxicity or seizure liability based on the inherent physiological characteristics of the neurological system, i.e. electrical activity, tissue architecture, synaptic structures, that is fit for purpose for use in the commercial sector.
Against this background it is an object underlying the invention to provide a new device which allows the interrogation and/or stimulation of neurons in 3D non-adherent networks in vitro, thereby creating a platform for studying neural functions, neurodegenerative disorders and testing potentially neuro-active substances. In particular, a device is to be provided which allows both the measuring of action potential propagation and synaptic transmission between connected neurons and the direct electrical stimulation of the neurites, both in the presence and absence of test substances, without interfering with the architecture and integrity of the neurons.
This object is met by providing a device for recording electrical activity of and/or stimulating neural cells in a three-dimensional neural network, comprising:
The inventors have surprisingly realized that with a device designed in the prescribed manner the measuring of neuronal excitability as well as the electrical stimulation along neurites arising from 3D neuronal architectures will become possible without interfering with the architecture and integrity of the neurons. The device according to the invention will therefore allow the testing of compounds for their neuro-active potential in the context of complex neuronal networks, such as potentially neuro-pharmacologically active drugs, environmental pollutants and pesticides etc.
According to the invention, the at least one microchannel comprise dimensions allowing the extension of neurites from said first compartment into said at least one microchannel and prevent the entry of the soma of neurons. The skilled person is perfectly aware of the dimensions of the microchannels to fulfill such preconditions as the dimensions of neurons or their neurites and soma are well described in literature. An exemplary however non-binding example of an appropriate microchannel of an embodiment of the invention comprises the following dimensions: approx. 3 μm high, approx. 3-4 μm wide, and approx. 100-500 μm and preferably approx. 300 μm long.
The at least one microelectrode integrated into the microchannel will allow the measuring or initiation of action potential propagation and synaptic transmission between neurons connected in 3D. Importantly, according to the invention the microelectrode is embedded into the microchannel in such a way that it comes in close vicinity with the neurites present in the microchannel without penetrating or injuring the neurite. The microelectrode can partially extend and/or protrude into the microchannel in such a way that it does not penetrate or injure the neurite. Preferably, however the microelectrode does not extend and/or protrude into the microchannel. Thereby, the microelectrode will not penetrate or injure the neurite. This offers the advantage over other electrophysiological techniques, such as patch-clamp used to record from 3D neuronal structures, of being non-invasive. Therefore, measurements and/or stimulations can be taken or effected repeatedly at any time-point during cultivation.
The “at least one compartment” may be completely enclosed, or may be open on one or more sides.
“At least one microchannel” means that there may be more than one microchannel or even a plurality of microchannels.
According to the invention, a “microelectrode” refers to any device capable of being integrated into a microchannel and recording electrical activity of and/or stimulating, preferably electrically, neural cells. A microelectrode has suitable properties to its function, including low impedance and low noise. The microelectrode may be made of a suitable material for performing its function, including but not limited to gold, platinum, iridium, iridium oxide, titanium nitride, carbon nanotubes, graphene, diamond, a conducting polymer such as poly(3,4-ethylenedioxythiophene) or combinations of these materials. The microelectrode may include a coating which enables or improves its function. The microelectrode may be positioned at different positions inside the microchannel. Further, there may be more than one microelectrode inside a channel. The microelectrode may be positioned on one side of the channel, may enclose the perimeter of the channel, may be smaller than the length of the channel, or it may cover the entire length of a channel.
The at least one microelectrode which is arranged to record electrical signals from neurites is referred to as “recording electrode”. The at least one microelectrode which is arranged to administer electrical signals to neurites is referred to as “stimulation electrode”. It is to be understood that the same microelectrode can have both functions, i.e. one microelectrode fulfills the activity of both of the recording electrode and the stimulation electrode. However, the recording electrode and the stimulation electrode can be provided as two distinct microelectrodes.
In an embodiment of the invention the device or parts thereof can be made from polymers, glass or ceramic, or a combination thereof. Such glasses include, by way of example, borosilicate glass or fused silica. Such ceramics include, by way of example, quartz, silicon oxide, or silicon nitride. Glasses and ceramics can be patterned by plasma etching, wet etching, and laser etching. Glasses and ceramics have advantages of thermal and chemical resistance. On the other hand, glasses and ceramics suffer from challenging fabrication. Suitable polymers include, by way of example, polydimethylsiloxane (PDMS). PDMS offers several advantages, such as easy fabrication, optical clarity and gas permeability. On the other hand PDMS can variably absorb small hydrophobic compounds, which may lead to changes in bioavailability for some compounds. For this reason alternative polymers such as SU-8 or other epoxy-based negative photoresists may be used to fabricate the device or parts thereof. SU-8 offers advantages such as the ability to fabricate high resolution multilayer structures not possible with other methods. However, SU-8 suffers from challenging fabrication, limited optical transparency and autofluorescence. For this reason alternative polymers such as cyclic olefin copolymers (COC) or cyclic-olefin polymers (COP) may be used to fabricate the device or parts thereof, preferably by injection molding.
According to the invention “three-dimensional network” refers to the spatial connection of neurons in a biocompatible matrix allowing the cultivation of the cells without adhering or contacting the walls or boundary surfaces of the compartment.
The object underlying the invention is herewith completely achieved.
In an embodiment of the invention said device is further comprising a second compartment configured for the cultivation of neurons, wherein a first connecting region comprises the at least one microchannel leading to said second compartment thereby connecting said first compartment with said second compartment.
In this embodiment the neurons were put and cultured in the first compartment, and neurites reach the second compartment via the at least one microchannel. Said first and second compartments may have the same features and characteristics. In particular, the may comprise spatial dimensions allowing the three-dimensional (3D) cultivation of the neurons, i.e. the formation of neuronal networks or circuits, respectively. In a non-binding exemplary embodiment of the invention, for this reason, the first and second compartments have the following dimensions: approx. >100 μm high, approx. >300 μm wide, and approx. >2 mm long.
In a further development of the invention the device is further comprising:
The features, characteristics and advantages mentioned further above for the first and second compartments, the first connecting region, the at least one microchannel and the microelectrode mutatis mutandis apply to the third compartment and the second connecting region, at least one the further microelectrode.
This embodiment of the invention results in the advantage that the measuring of neuronal excitability as well as the electrical stimulation will become possible along more than one but two or more neurons or neurites connected in series along different compartments. Furthermore, in an embodiment of the invention this configuration will allow the provision of a stimulation microelectrode embedded into the microchannel(s) of the first connecting region and of a recording microelectrode embedded into the second connecting region or vice versa. Such configuration may help to establish a complex experimental set-up where the influence of test compound on the progression of induced electrical impulses could be examined.
It goes without saying that the device according to the invention may comprise more than three compartments, but multiple compartments, i.e. four, three, five, six, . . . , ten, twenty, thirty, . . . etc., connected by connecting regions each comprising at least one microchannel.
In another embodiment of the invention the microelectrode is realized and/or comprises a transducer.
This measure has the advantage that a particularly well suited kind of microelectrode is used. A transducer includes the recording and stimulation sites of Complementary Metal-Oxide-Semiconductor (CMOS) devices such as CMOS-MEAs.
In another embodiment of the invention said at least one microchannel and/or said at least one further microchannel comprise multiple microelectrodes.
This measure has the advantage that electrical signals can be recorded and/or electrical pulses can be administered at different sections of the neurites. The multiple microelectrodes may be of the same type, thereby allowing a more precise recording and/or more effective stimulation. The multiple electrodes may also be of different types allowing various signal recordings and/or stimulations.
In another preferred embodiment of the invention said first connecting region comprises a plurality of said microchannel and/or said second connecting region comprises a plurality of said further microchannel.
This embodiment allows the recording and stimulation at numerous neurites in parallel, thereby gaining data which reflect the physiological conditions in the brain in an improved manner.
A “plurality” refers to up to about 50 to about 500 or more microchannels per connecting region.
In another embodiment said dimensions of said microchannel and/or said further microchannel comprise at its/their smallest dimension(s) a diameter of <5 μm, preferably of about ≤4 μm, further preferably of about ≤3 μm, further preferably of about ≤2 μm, further preferably of about ≤1 μm, further preferably of about ≤0.5 μm, further preferably of about ≤0.4 μm, further preferably of about 0.3 μm, further preferably of about 0.2 μm, and further preferably of about 0.1 μm.
By this measure the constructive preconditions are provided ensuring dimensions allowing the extension of neurites from the compartments into the microchannels but preventing the entry of the soma of neurons.
In an embodiment of the invention multiple devices, e.g. such as about 2 to 12 devices, as characterized herein are assembled, thereby forming a device assembly comprising multiple functional units. This will allow the running of multiple separate assays in parallel, thereby qualifying the invention as a valuable tool for high throughput applications.
In another further development of the invention at least one of said first and second and third compartments comprises an opening on its top, preferably at least one of said first and second and third compartments is open on top.
“Opening or open on top” means that the compartments are accessible from outside. This measure has the advantage that e.g. cell culture media or test substances etc. can be easily added to the cells.
In a preferred further development of the device according to the invention said first and second and said third compartments comprise reservoirs terminal to said channels, further preferably said reservoirs are configured for the seeding of neurons and/or delivery of additives, such as culture media and/or test compounds.
The “reservoir” comprises a volume that is larger than the volume of the channel part of the compartments. It also may comprise an opening on top which is larger than the opening of the compartments. The reservoir therefore facilitates the plating of the neurons into the device and the addition of media, test compounds etc.
In another further development of the device according to the invention said reservoirs comprise a cell seeding area.
The cell seeding area may comprise a physical barrier allowing the defined seeding of the neurons separate from the remaining area of the reservoir. As an example, the cell seeding area may be realized by a subsidence or depression in the base of the reservoirs, e.g. in a central position thereof. Due to its physical separation the cell seeding area also allows the deposition of a scaffold for the growing of the neurons in 3D, such as a hydrogel, which may fill the cell seeding area and may be connected with at least parts of the channels.
In another further development of the invention at least one of said first and second and third compartments comprises a lower sub-compartment and an overlying top sub-compartment adjacent thereto, preferably said microchannels lead to said lower sub-compartment.
The lower and overlying top sub-compartments are physically distinct from each other, while, at the same time, connected with each other. The measure allows, e.g., the filling of the lower compartment with a scaffold for the growing of the neurons in 3D such as a hydrogel, and of the overlying top-compartment with cell culture medium or buffer etc. where test substances may be added to. The test substances may then and diffuse through the medium or buffer and the scaffold to the neurons.
In a preferred configuration the microchannel(s) lead or open out into the lower sub-compartment. This has the advantage that neurites growing from the non-adherent neurons find and extend into the microchannels near to the bottom of the microfluidic part of the device which, in turn, creates the condition for a simple fitting of the microelectrodes from the bottom or the underside, respectively.
In another further development of the invention said lower sub-compartment comprises a width or diameter which is wider than the width or diameter of said top sub-compartment.
By this measure the constructive conditions for a physical delimitation of the lower and overlying sub-compartments are realized. The broadening of the lower sub-compartment over the top compartment facilitates the separation of the scaffold or hydrogel from the overlying medium. A paradigmatic and non-limiting example of the dimensions is as follows. Lower sub-compartment: approx. 400 μm wide; top compartment: approx. 300 μm wide. In an embodiment of the invention the lower sub-compartment may have a height of approx. 150 μm and, independently, the top compartment may have a height of approx. 2 mm.
In a further development of the microfluidic device of the invention at least one of said first and second and, optionally, third compartments comprises at least a transparent material, such as glass.
“Transparent” in this context means optically clear in a way that the cultivated neurons can be visualized with a fit for purpose microscope through the device according to the invention. The optical path runs through the top of the devices, the neurons and the bottom. This measure has the advantage that due to the optical clarity of parts of the compartments and/or the device the acquisition of structural data of such 3D multi-cellular architectures may be captured with sub-cellular resolution, e.g. by confocal microscopy. The transparency may be realized by a glass plate, e.g. a glass MEA configured in a way as to provide the microelectrodes below the microchannel(s). Other transparent materials may be used such as optically clear polymers. It goes without saying that the entire microfluidic device may be made of optically clear materials.
Another subject-matter of the invention relates to a method for examining neurons, comprising the following steps:
The features, characteristics, further developments and advantages mentioned for the device according to the invention apply likewise to the method according to the invention.
In a further development of the method according to the invention said first compartment is connected via a first connecting region with a second compartment, said first connecting region comprising said at least one microchannel leading to said second compartment thereby connecting said first compartment with said second compartment, and the neurites of said neurons are allowed to grow through said at least one microchannel towards said second compartment.
In an alternative embodiment of the method according to the invention the neurons can be cultivated in the second and/or third compartment. The neurons will then pass through the first connecting region or, optionally, the second connecting region to said first and/or second and/or third compartment and/or vice versa. It is to be understood that, in another embodiment of the invention, the neurons can be cultivated in all of the compartments in parallel.
In a further development of the method according to the invention said cultivating is carried out in a scaffold allowing a three-dimensional cultivation of said neurons, preferably in a hydrogel or a fibrous matrix.
This measure has the advantage that preferred structures are provided which favor the three-dimensional cultivation of the neurons.
In another embodiment of the method according to the invention in addition to or instead of said neurons non-neuronal cells are cultivated.
Such measure has the advantage that a situation is established resembling even more the physiological situation where non-neuronal cells take over other functions such as support functions.
In another embodiment the three-dimensional matrix includes neurospheres and/or minibrains and/or brain organoids.
This measure takes advantage of using more heterogeneous structures comprised by the 3D neuronal architectures.
In another development of the method according to the invention additives, preferably test compounds, are added to said first and/or second or, optionally third compartment.
It is to be understood that the before-mentioned features and those to be mentioned in the following cannot only be used in the combination indicated in the respective case, but also in other combinations or in an isolated manner without departing from the scope of the invention.
The features mentioned in the specific embodiments are also features of the invention in general, which are not only applicable in the respective embodiment but also in an isolated manner in the context of any embodiment of the invention.
The invention is also described and explained in further detail by referring to the following drawings.
In
In
As it can be inferred from
In
In a preferred but non-limiting embodiment of the device assembly 10 each connecting region 24 comprises 32 microelectrodes 26, each functional unit 12, therefore, comprises 64 microelectrodes 26 and the entire device assembly 10 comprises 256 microelectrodes 26.
For cultivation the cells are seeded in the cell seeding areas 16c of the second compartment 16 in a hydrogel scaffold which fills the lower sub-compartments 14a′, 16a′, 18a′ up to the border to the top sub-compartments 14a″, 16a″, 18a″. Neurites can extend into the neighboring first 14 and third compartment 18 by growing through the microchannels 22. The microelectrodes 26 integrated below each of the microchannels 22 record action potentials along single neurites or may apply electrical pulses thereon.
In
In
In
In
General:
An MEA having a footprint of 49 mm×49 mm and containing 256 integrated recording microelectrodes, arranged in a 4×64 matrix, is designed and fabricated. Patterning of microelectrodes-aligned microchannels (3 μm high, 7.5 μm wide, 300 μm long) on the upper surface of MEA is achieved by photolithography of SU-8.
At the same time, a range of different designs, materials and fabrication processes is evaluated for their capacity to consistently produce the microfluidic part of the device assembly (32 mm wide, 32 mm long, 3 mm high) compatible with the goal of growing cells in 3D. In particular, materials like COC and COP, considered industry standards for biopharmaceutical applications, are tested for injection moulding. Materials like glass are tested for selective laser etching. The material is tested for the successive MEA bonding process (by solvent bonding or thermal bonding or chemical bonding) as well as for the purpose of culturing viable 3D neuronal networks.
After bonding, the new hybrid MEA/microfluidic device is subjected to biological testing and functional characterization.
Design and Mastering:
The design of the microfluidic device assembly can be transferred to a design for mass manufacturing. After taking care of typical design rules for injection moulding and adapting the design accordingly, metal inserts can be manufactured by micro-milling. Depending on the complexity a new base mould might be required during the development.
Injection Moulding:
After realising the insert for the mould, injection tests can be performed with different materials e.g. different grades of COC or COP. This will enable to test and to compare different properties of the moulded material for the succeeding bonding process as well as in the final application.
Selective Laser Etching:
The design of the microfluidic device assembly can be transferred to a design for mass manufacturing. After taking care of typical design rules for selective laser etching and adapting the design accordingly, glass microfluidic parts can be produced by selective laser etching.
Bonding:
The MEA can be manufactured such that the upper surface will be micro-patterned by a photolithographic process based on SU8. During the bonding task the moulded part may be permanently attached to this SU8 layer. Bonding of injection moulded parts may be done by solvent bonding or thermal bonding or chemical bonding. A bonding process of COC/COP or glass to SU8 is used which will not destroy the micro-features on SU8 and has a sufficient bonding strength for the application.
Characterisation and Application Tests:
Characterisation and application tests are performed in parallel. Characterisation includes: geometrical measurements by scanning electron microscopy (SEM), profilometry and transparency checks. Application tests can start in parallel to the bonding tests. This will give first hints about the bonding strength and how this is affected by the different strategies used for bonding.
Combining Structural and Functional Readouts:
Due to the optical clarity of the device, capturing structural data by live microscopy will allow reconstructing 3D neuronal morphologies in detail. A recent study performed by the inventors has shown how by using high resolution confocal microscopy it was possible to identify fine neuronal ultra-structures, such as dendritic spines, in live 3D neurons cultured on matrigel scaffolds. Recording neuronal activity by microelectrodes offers the advantage, over other electrophysiological techniques, of being non-invasive. Therefore, measurements can be taken repeatedly at any time-point during cultivation. In combination to imaging experiments this offers the unique possibility to combine continuous acquisition of structural and functional parameters from 3D cultured neurons into a single live assay.
Platform Validation:
This will be carried out in order to verify the capacity of the device according to the invention to identify and predict a range of interactions between specific classes of compounds and neuronal pathways. Electrophysiological and structural read-outs can be both employed to monitor the responses to a small ad selected group of reference compounds. This will ensure that the most relevant molecules will be selected, according to a list of criteria such as: i) chemical structure, ii) applications routes (nervous system drugs, other-organ drugs, pesticides) and iii) range of engaged cellular pathways. For testing purposes, the compounds can be divided into 3 calibration sets, containing 5 compounds each (3 positive and 2 negative controls), for the purpose of identifying subtypes of response patterns:
Throughput:
Each microfluidic device assembly, with a footprint of only 49 mm×49 mm, may contain a total of 256 microelectrodes, arranged in a matrix of up to 12×21 microelectrodes. This will ensure multiple independent experiments on each functional unit, each having enough microelectrodes to sample a large number of neurons. A range of compound concentrations plus control solutions could be run on each chip, providing enough through-put to support rapid screening campaigns.
Cost-Efficiency:
Due to the compact size of the microfluidic device assembly, running each single assay will only require a few thousand cells and less than 100 μl of test compounds. This means, for example, that one vial of human iPS cells, containing 1-2 million cells on average, will be sufficient for up to 60 independent measurements. This, considering the very high prices of iPS cells, will contribute to keep costs at an acceptable level for this type of assay.
Bio-Compatibility:
Most microfluidic devices currently used to create organs-on-chip are made in PDMS. Although this material offers several advantages, such as easy fabrication, optical clarity and gas permeability, on the other hand PDMS can variably absorb small hydrophobic compounds, which may lead to changes in bioavailability for some compounds. For this reason alternative materials such as COC or COP or glass, gold standards in biopharmaceutical testing, can be used to fabricate the microfluidic chip. Although this will require a more complex process for production of the device and thermal or solvent or adhesive bonding to attach it to the MEA substrate, the use of such materials is considered advantageous considering its intended screening purposes.
Long-Term 3D Cultivation:
Achieving long-term cell survival in hydrogel scaffolds requires a controlled flow of culture media through the microfluidic chip. The media is in fact used to exchange gases between air and the gel, to provide nutrients and remove metabolites, to apply compounds during drug testing. These features will be implemented in the microfluidic device assembly design, based on a channel containing a hydrogel lane (400 μm wide, 150 μm high) at the bottom of the device (lower sub-compartment) and a liquid lane (300 μm wide, up to 2 mm high) on top of the gel lane (top sub-compartment). In this way media/solutions/drugs can be easily applied/replaced at the top liquid lane via reservoirs and from here they can rapidly diffuse to the cells contained in the bottom gel lane.
Handling:
Liquid handling and drug applications will be done as described above, using an open system that does not require any specific equipment, as all liquids in the top lane will move between the reservoirs passing through open channels having low resistance. This provides the option to add robotic control of all liquid handling steps, as eventually required for screening purposes.
Cross-Platform Functionalities:
With a footprint of only 49 mm×49 mm and an optically-clear glass bottom, the microfluidic device according to the invention will be available for capturing simultaneously electrophysiological and imaging data using standard MEA recording apparatus and confocal/scanning disk microscopy. Microelectrode arrays can be designed compatible to the format of recording hardware/software produced by commercial providers.
The inventors have successfully tested the microfluidic device assembly for its capability to cultivate and examine neurons in the context of 3D neuronal networks.
Emulating 3D Brain Networks:
To partially reconstruct the complex multi-cellular structure of the human brain, commercially available neuronal (excitatory and inhibitory) and glial (astrocytes) cells derived from human iPSCs are grown in 3D inside the microfluidic device assembly, using a range of biomimetic hydrogel scaffolds (bio-derived or synthetic). In order to evaluate cell viability, neuronal outgrowth and 3D architectures obtained using different microfluidic designs, materials and cell types, live imaging experiments are carried out by labelling cells with a range of genetically-encoded fluorescent proteins. Using this approach the inventors obtained data with various prototype devices showing GFP-labelled neurons growing extensively in 3D within few days from seeding.
Recording Neuronal Activity from 3D Networks:
As neurites elongate through the dedicated microchannels at the bottom of the microfluidic device assembly according to the invention, microelectrodes integrated below each microchannel will allow measuring action potential propagation and synaptic transmission between neurons connected in 3D. Different microelectrodes sizes and positions within the microchannels are evaluated to identify the ideal dimensions to obtain the best signal-to-noise ratio. The inventors obtained proof-of-concept results showing that iPSC-derived neurons cultured in 3D (
As can be seen from
| Number | Date | Country | Kind |
|---|---|---|---|
| 17206438.8 | Nov 2012 | EP | regional |
This application is a continuation of copending international patent application PCT/EP2018/083715 filed on 6 Dec. 2018 and designating the U.S., which has been published in English, and claims priority from European patent application EP 17 206 438.8 filed on 11 Dec. 2017. The entire contents of these prior applications are incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/EP2018/083715 | Jun 2012 | US |
| Child | 16899297 | US |
